Correction to: Breast Cancer Research and Treatment https://doi.org/10.1007/s10549-019-05166-3
Unfortunately in the original publication of the article, the author’s funding support has been mentioned incorrectly. The correct funding statement should read as “This work was supported by the Morgan Welch Inflammatory Breast Cancer Research Program, the State of Texas Rare and Aggressive Breast Cancer Research Program, MD Anderson’s Cancer Center Support Grant (P30CA016672, used the Characterized Cell Line Core Facility and Flow Cytometry and Cellular Imaging Facility), and Spirita Oncology, LLC.”
The first affiliations was incorrect in the original article. The correct information is given below.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Lee, J., Lim, B., Pearson, T. et al. Correction to: Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer. Breast Cancer Res Treat 176, 251 (2019). https://doi.org/10.1007/s10549-019-05218-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-019-05218-8